UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or org ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Phil Deschamps - Chairman, President & Chief Executive Officer Joyce LaViscount - Chief Financial Officer & Chief Operations Officer Conference Call Participants Jeff Porter - Porter Capital Anthony Lamport - The Lambda Funds Operator Good evening, ladies and gentlemen, and welcome to the First Quarter of Fiscal Year 2020 Earnings Conference Call for Helius Medical Technologies. At th ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2019 Earnings Conference Call March 12, 2020 5:00 PM ET Company Participants Phil Deschamps - Chairman, President and Chief Executive Officer Sukhvinder Kalsi-Ryan - Affiliate Scientist, Kite Research Institute; and Member of the University Health Network Joyce LaViscount - Chief Financial Officer and Chief Operations Officer Conference Call Participants Jeff Porter - Porter Capital Anthony Lamport - The Lambda Funds Operator Good evening, ladies and gentle ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from _____ to _____ Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-4787690 (State or other juris ...

Financial Data and Key Metrics Changes - The company reported total revenue of $150,000 for Q3 2019, compared to no revenue in the prior year period [44] - Gross profit for Q3 2019 was $61,000, with operating expenses increasing by $907,000 or 19% year-over-year to $5.8 million [45] - Operating loss for Q3 2019 was $5.7 million, compared to an operating loss of $4.9 million for the prior year period [49] - The net loss for Q3 2019 was $5.6 million or $0.21 per share, compared to a net loss of $4.5 million or $0.19 per share for Q3 2018 [50] Business Line Data and Key Metrics Changes - Revenue in Q3 was primarily driven by sales of PoNS devices to three new clinics in Toronto, Calgary, and Ottawa [44] - Patient treatment starts were 23 in Q1, 38 in Q2, and 32 in Q3, with a modest decline in Q3 attributed to scheduling issues during summer vacations [23][24] Market Data and Key Metrics Changes - The company reported 66 million impressions from marketing efforts, resulting in 4 million video views and 356 clinic consultations during the quarter [28] - The primary drivers of patient starts in Q3 were the founding clinics in Montreal and Surrey, along with three new clinics that became operational [24] Company Strategy and Development Direction - The company is focused on expanding access to PoNS treatment by increasing the number of authorized clinics and pursuing marketing initiatives to raise awareness [25][27] - A strategic decision was made to acquire Heuro Canada to improve commercial efficiency and accelerate the adoption of PoNS technology [33][34] - The company aims to secure reimbursement from insurers for treatments, having already obtained two fully reimbursed patient treatments [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early commercialization progress and the potential for continued growth in Q4 2019 [60] - The company is actively engaged with the FDA to refine its strategy for resubmitting an application for de novo classification of the PoNS device [39][41] Other Important Information - The company updated its revenue guidance for 2019 to a range of $1.5 million to $1.6 million, down from the previous range of $1.6 million to $2 million [57] - The company had approximately $9 million in cash as of September 30, 2019, down from $25.6 million at the end of 2018 [51] Q&A Session Summary Question: Can you talk about increased traffic at the open PoNS centers in Canada as a result of some of the online work that you've done? - Management noted 356 engagements in clinics, with a mix of early adopters and those waiting for reimbursement [67][68] Question: Can you talk about the reimbursement levels established in the two instances mentioned? - Reimbursement amounts were between $22,000 and $30,000 for the two treatments, with efforts to template successful reimbursement patterns for broader application [71][72] Question: Can you provide a range of what the burn is expected to go down to in Q4? - Management indicated that the burn rate would be reduced, excluding costs associated with the Heuro acquisition [79] Question: How will the company finance itself during 2020? - Management is exploring all possible ways to raise funds while focusing on protecting existing shareholders [85]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer ...

For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File No. 001-38445 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Phil Deschamps - CEO Joyce LaViscount - CFO & COO Conference Call Participants Marie Thibault - BTIG Operator Good afternoon, ladies and gentlemen, and welcome to the First Quarter of Fiscal Year 2019 Earnings Conference Call for Helius Medical Technologies. [Operator Instructions] Please note that this conference is being recorded, and that the recording will be available on the comp ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Delaware 36-4787690 (State or other jurisdiction of ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2018 Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants Phil Deschamps - CEO Joyce LaViscount - CFO and COO Conference Call Participants Steven Lichtman - Oppenheimer Sean Lavin - the BTIG Operator Good afternoon ladies, and gentlemen and welcome to the Fourth Quarter of Fiscal Year 2018 Earnings Conference Call for Helius Medical Technologies. At this time, all participants have been placed in a listen-only mode. Please note that this ...